How to Protect Your Kidney Function During Lu-177 PSMA Therapy for Bone Metastases — What the Evidence Says About Monitoring and Support

When You Learn Lu-177 PSMA Therapy Might Be an Option — and You Are Worried About Your Kidneys

Your prostate cancer has spread to your bones. Your oncologist has mentioned Lu-177 PSMA therapy as a possible next step. You want to understand what that means. And one of the first questions many men ask is this: what does this treatment do to my kidneys?

That concern makes sense. Lu-177 PSMA therapy delivers radiation directly to cancer cells. But it doesn't stay only in cancer cells. The kidneys help clear this therapy from your body. As a result, they receive some radiation during the process.

This article explains what the evidence actually shows about kidney safety during Lu-177 PSMA therapy. It covers how doctors monitor kidney function, what warning signs to watch for between appointments, and what practical steps may help support your kidney health during treatment.

How Lu-177 PSMA Therapy Works — and Why the Kidneys Are Involved

Lu-177 PSMA therapy (brand name Pluvicto, generic name lutetium Lu 177 vipivotide tetraxetan) was approved by the U.S. Food and Drug Administration in March 2022 for men with PSMA-positive metastatic castration-resistant prostate cancer who had already received androgen receptor pathway inhibitors and taxane-based chemotherapy.

The treatment works by attaching a radioactive molecule (lutetium-177) to a targeting molecule called a PSMA ligand. The ligand seeks out prostate cancer cells that carry a protein called PSMA (prostate-specific membrane antigen) on their surface. When it finds those cells, it delivers radiation to them directly.

Here's where the kidneys come in. After each infusion, your body filters and clears the radioactive compound through the urinary system. The kidneys do most of this work. As the compound passes through kidney tissue, it exposes that tissue to radiation. Kidney cells naturally carry small amounts of the PSMA protein, so they absorb a small amount of the radioactive material before it leaves your body.

This doesn't mean your kidneys are in serious danger. But it does mean that monitoring kidney function at every treatment stage is a standard and important part of safe care.

Who May Be at Higher Risk for Kidney Changes During Treatment

Most men who receive Lu-177 PSMA therapy do not develop serious kidney problems. But research has identified certain factors that may increase the chance of gradual kidney changes over time. These include:

• Older age — kidney function naturally declines with age, independent of cancer treatment
• High blood pressure (hypertension) — one of the most common contributors to kidney decline in the general population
• Pre-existing kidney disease — if your eGFR is already below the normal range, your care team will monitor it more closely
• Diabetes — long-term diabetes can reduce the filtering capacity of the kidneys over time
• Prior exposure to nephrotoxic treatments — some chemotherapy drugs used in prostate cancer care can affect kidney function

Having one or more of these risk factors doesn't automatically rule you out. Your team will create a closer monitoring plan for your specific situation and may take extra steps at each stage of treatment.

To understand how kidney function fits into the broader eligibility picture, see our guide: Am I a Candidate for Lu-177 PSMA Therapy? A Plain-Language Guide to Eligibility for Men with mCRPC.

What the Clinical Evidence Shows About Kidney Safety

The most important evidence comes from the VISION trial (the large phase 3 clinical study that led to FDA approval). A sub-study within VISION looked at how much radiation the kidneys received and whether it caused measurable damage.

According to the VISION dosimetry sub-study published in the Journal of Nuclear Medicine, the average kidney dose was about 0.43 Gy per GBq in the first cycle, with a total of about 15 Gy across all six cycles. Importantly, no patients experienced serious or life-threatening kidney damage (grade 3 or 4 toxicity).

A separate study looked at patients who already had lower kidney function before starting treatment. According to a study on renal safety in patients with compromised baseline kidney function, none of them developed severe kidney damage (grade 3 or 4). In some cases, kidney function actually improved during treatment, which researchers linked to successful cancer control.

Overall, the evidence shows that serious kidney damage is uncommon during this therapy when standard monitoring is in place.

How Your Care Team Monitors Your Kidney Function During Treatment

Kidney monitoring is not an afterthought during Lu-177 PSMA therapy. It is built into the treatment plan at every stage. The Joint EANM/SNMMI procedure guideline for Lu-177 PSMA therapy — the international standard published by leading nuclear medicine societies — recommends formal kidney function assessment before each treatment cycle and after treatment is complete.

In practice, monitoring typically includes:

• Serum creatinine and eGFR (estimated glomerular filtration rate) — measured before every cycle using a standard formula to track how well the kidneys are filtering waste
• Cystatin C — research suggests this may be a more sensitive early marker for detecting kidney changes than creatinine alone, and it is used in some specialist centers
• Blood urea nitrogen (BUN) — an additional marker of kidney filtering capacity
• Urine protein tests — protein appearing in the urine can signal early kidney stress even when blood markers are still normal
• Blood pressure monitoring — uncontrolled hypertension both causes and accelerates kidney decline, so managing it is part of kidney protection
• Nuclear medicine renal scan (MAG-3 scintigraphy) — used at some specialist centers to assess each kidney individually before treatment begins, providing a detailed functional baseline

If your eGFR starts to decline or other markers get worse, your care team may adjust when your next cycle is given, change the dose, or take a break to let your kidneys recover. These adjustments are planned responses, not emergencies, and show how specialist centers protect patients.

Practical Steps That May Support Your Kidney Health During Treatment

While your medical team manages the clinical side of monitoring, there are steps you can take between appointments to support your kidney health during treatment.

• Stay well hydrated. Good fluid intake may help your kidneys clear the radioactive compound more efficiently in the days following each infusion. Your nuclear medicine team will give you specific guidance on fluid intake after each treatment session.
• Avoid or minimize NSAIDs. Over-the-counter pain relievers such as ibuprofen and naproxen can strain the kidneys. If you need pain relief during treatment, discuss safer alternatives with your oncologist.
• Keep blood pressure under control. If you have hypertension, managing it well throughout treatment is one of the most direct ways to protect kidney function across multiple cycles.
• Share a complete medication list with every member of your care team. Some medications — including certain antibiotics, contrast dyes used in imaging, and some herbal supplements — can affect kidney function. Your team needs a complete picture.
• Attend all scheduled blood tests. Kidney changes during treatment can be completely silent — you may feel no different. Lab tests are the only reliable way to detect changes early, when they are still manageable.

What If You Already Have Reduced Kidney Function?

This is among the most common concerns from men with bone-metastatic prostate cancer. Many have already completed chemotherapy or other treatments that can affect the kidneys. Others have age-related kidney decline, long-standing hypertension, or diabetes.

Mild to moderate reduction in kidney function doesn't automatically rule out Lu-177 PSMA therapy. Decisions are made case-by-case. An experienced physician considers your current eGFR, how your kidney function has changed, your overall health, and the expected benefit for your situation.

If you've been told your kidney function is below normal, request a specialist review before assuming you can't get treatment. An experienced center can adjust monitoring and timing to protect your kidneys while delivering effective treatment.

For a broader understanding of how side effects are managed during this therapy, see: What Are the Real-World Side Effects of Lu-177 PSMA Therapy for mCRPC — and How Do Doctors Manage Them?

How Kidney Risk in Lu-177 PSMA Therapy Compares to Other Treatment Options

All systemic treatments for metastatic prostate cancer carry some organ risk. Docetaxel and cabazitaxel chemotherapy can affect the nervous system, bone marrow, and other systems. Some androgen receptor inhibitors require liver monitoring. No therapy is without trade-offs.

What makes Lu-177 PSMA therapy different is how precisely it targets cancer. Because it seeks out PSMA-expressing cells, radiation goes to the tumor rather than spreading throughout the body. Kidney exposure is real and monitored, but evidence shows it's manageable for most patients at specialist centers.

What International Patients Should Expect Around Kidney Monitoring When Treating in India

If you are planning to travel to India for Lu-177 PSMA therapy — whether from the United Kingdom, Australia, Canada, the United States, the UAE, or elsewhere — kidney monitoring will be built into your treatment plan just as it is at leading centers in Europe and North America. Specialist nuclear medicine centers in India that offer this therapy follow the same international protocols, including EANM/SNMMI standards, for pre-treatment kidney assessment and cycle-by-cycle monitoring.

Before your first treatment cycle, your care team will review your submitted blood test results and establish a baseline picture of your kidney function. Between treatment cycles — which are typically spaced six weeks apart — you can arrange blood tests through your local doctor or a nearby laboratory and share the results electronically with the Indian center. This keeps monitoring continuous even while you are not physically at the clinic.

Your patient navigator will help coordinate this process, making sure your care team has up-to-date kidney function data before each cycle is approved to proceed.

For detailed guidance on logistics and preparation for treatment travel, see: Planning Your Lu-177 PSMA Treatment Cycle in India: A Medical Preparation and Travel Guide for International Patients.

Submit Your Medical Records for a Specialist Kidney Safety Review

If you are weighing Lu-177 PSMA therapy as a next step and want to understand whether your kidney function is compatible with treatment, a specialist review of your current medical records is the right place to start. Our patient navigators work with nuclear medicine physicians who can assess your specific kidney markers alongside your PSMA PET scan results and full treatment history.

You are welcome to submit the following for a confidential eligibility review:

• PSMA PET scan report or Ga-68 PSMA PET-CT report
• Recent blood test results, including creatinine, eGFR, cystatin C, and BUN if available
• Histopathology or biopsy report
• Full prostate cancer treatment history
• Imaging reports showing extent of bone metastases
• Current medication list

A specialist will review your records and advise on eligibility, what kidney monitoring would look like for your specific case, and what treatment planning in India involves.

When to Talk to Your Doctor

Speak to your oncologist or nuclear medicine specialist if you have any of the following concerns before or during Lu-177 PSMA therapy:

• A known history of kidney disease or a current eGFR below the normal range
• High blood pressure that is not well controlled
• A history of diabetes that has affected your kidneys
• New or worsening swelling in your legs, ankles, or feet
• Changes in the amount or color of your urine
• Foamy urine, which may signal protein loss through the kidneys
• Questions about whether your current kidney function makes you eligible for this therapy

These conversations are most useful before treatment begins. The more your care team knows about your kidney health at baseline, the better they can tailor monitoring to protect you throughout your treatment course.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.